期刊文献+

糖尿病肾病患者血管活性物质检测的临床意义 被引量:1

Clinical significance of detection of vasoactive substances in patients with diabetic nephropathy
下载PDF
导出
摘要 目的:探讨糖尿病肾病(DN)患者血管活性物质检测的临床意义。方法:选择2型糖尿病患者138例作为研究对象,根据24h尿微量白蛋白(MAU),分为单纯糖尿病组(DM组)、早期糖尿病肾病组(EDN组)和临床糖尿病肾病组(CDN组),同时选择年龄和性别相匹配的35例健康者作为对照组,测定各组患者血管活性物质(ET、Ang-Ⅱ、TXB2、NO)和MAU水平并进行比较。结果:DM组、EDN组和CDN组的炎症因子与MAU均高于健康对照组(P<0.05);从DM组、EDN组至CDN组,MAU越来越高,ET、Ang-Ⅱ、TXB2逐渐增高,NO逐渐下降,各组患者相比具有统计学意义(P<0.05);MAU与ET、Ang-Ⅱ、TXB2呈正相关(P<0.05),与NO呈负相关(P<0.05)。结论:循环血液中的血管活性物质水平与DN的肾损害程度相关,可以作为DN的诊断和预后的可能指标。 Objective:To investigate clinical significance of detection of vasoactive substances in patients with diabetic ne-phropathy ( DN) . Methods:138 patients with type 2 diabetes mellitus were selected as research subjects and divided into diabetes mel-litus group ( DM group) , early diabetic nephropathy group ( EDN group) and clinic diabetic nephropathy group ( CDN group) accord-ing to 24h microalbuminuria (MAU), and 35 health people with matched ages and sex were used as control group. The vasoactive sub-stances (ET, Ang-Ⅱ, TXB2, and NO) and 24h MAU were measured and compared among each group. Results: The inflammatory factors and MAU in DM group, EDN group and EDN group were significantly higher than those in control group (P〈0. 05). From the DM group, EDN group to CDN group, ET, Ang-Ⅱ, TXB2 and MAU increased gradually, while NO decreased gradually, and there were statistical significance among each group (P〈0. 05). It showed there were positive correlations among ET, Ang-Ⅱ, TXB2 and MAU (P〈0. 05) and there was a negative correlation between NO and MAU (P〈0. 05). Conclusions: The vasoactive substances in the circulating blood are related with the degree of renal injury, and can be the possible indicators for the diagnosis and prognosis of DN.
作者 张桂菊
出处 《中国民康医学》 2014年第13期4-6,共3页 Medical Journal of Chinese People’s Health
关键词 糖尿病肾病 血管活性物质 尿微量白蛋白 Diabetic nephropathy Vasoactive substances Microalbuminuria
  • 相关文献

参考文献4

二级参考文献61

  • 1王海燕.肾脏病学.第3版.北京:人民卫生出版社,2009.1929-1931.
  • 2Jefferson JA, Shankland SJ, Piehler RH. Proteinuria in diabetic kidney disease : a mechanistic viewpoint [ J ]. Kidney Int, 2008,74 (1) :22 -36.
  • 3Siemianowicz K, Francuz T, Gminski J, et al. Endothelium dysfunction markers in patients with diabetic retinopathy [ J ]. Int J Mol Med,2005,15 (3) :459 - 462.
  • 4Rosenfeld MG, Mermod J J, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature, 1983,304:129-135.
  • 5Sun W, Wang L, Zhang Z, et al. Intramuscular transfer of naked calcitonin gene-related peptide gene prevents autoimmune diabetes induced by multiple low-dose streptozotocin in C57BL mice. Eur J Immunol, 2003,33:233-242.
  • 6Rayan SS, Hamdan AD, Campbell DR, et al. Is diabetes a risk factor for patients undergoing open abdominal aortic aneurysm repair? Vasc Endovascular Surg, 2002,36:33-40.
  • 7Martins D, Norris K. Combating diabetic nephropathy with drug therapy.Curr Diab Rep, 2001, 1:148-156.
  • 8Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin Ⅱ in DN.Kidney Int, 2000,58: s93-s98.
  • 9Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type I diabetes. Am J Med, 1985, 78: 785-794.
  • 10Matsushima M, Tajima N, LaPorte RE, et al. Markedly increased renal disease mortality and incidence of renal replacement therapy among IDDM patients in Japan in contrast to Allegheny County, Pennsylvania, USA. Diabetes Epidemiology Research International (DERI) U S Japan Mortality Study Grouo. Diabetolozia. 1995. 38: 236.

共引文献90

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部